非酒精性脂肪性肝病并发2型糖尿病患者血尿酸水平变化及其临床意义

doi:10.3969/j.issn.1672-5069.2021.01.015

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)并发2型糖尿病(T2DM)患者血尿酸(SUA)水平变化及其临床意义。方法 2015年6月～2019年12月我院收治NAFLD患者316例,其中并发T2DM患者218例,未并发T2DM患者98例,采用单因素和多因素Logistic回归分析确定与T2DM发生相关的独立危险因素。结果并发T2DM组男性比例显著高于非T2DM组(59.6%对42.9%,P<0.05),体质指数(BMI)为(27.2±2.9)kg/m²,显著高于非T2DM组,糖化血红蛋白(HbA1C)水平为(9.2±2.1)%,显著高于非T2DM组,血高密度脂蛋白(HDL)水平为(0.9±0.2)mmol/L,显著低于非T2DM组,甘油三酯(TG)水平为(1.9±0.5)mmol/L,显著高于非T2DM组,SUA水平为(335.8±72.6)μmol/L,显著高于非T2DM组,估算的肾小球滤过率(eGFR)为(158.4±40.6)ml/min/1.73m²,显著高于非T2DM组,空腹胰岛素(FINS)水平为(5.1±2.6)mIU/L,显著高于非T2DM组,胰岛素抵抗指数(HOMA-IR)为(1.9±1.1),显著高于非T2DM组;将性别、BMI、HbA1c、HDL、TG、SUA、eGFR、FINS和HOMA-IR作为自变量,将NAFLD患者是否并发T2DM作为因变量,纳入多因素Logistic回归分析,结果显示性别、HbA1c、SUA、FINS和HOMA-IR是NAFLD并发T2DM的独立危险因素(P<0.05),而BMI、HDL、TG和eGFR并不是影响NAFLD并发T2DM的独立危险因素(P>0.05);根据不同SUA水平将其从低到高分为SUA-1、SUA-2和SUA-3组,结果在218例合并糖尿病患者中,3组人群糖尿病占比分别为21.5%、32.1%和46.3%,差异显著(P<0.05),在88例女性NAFLD并发2型糖尿病患者中,其占比分别为10.2%、28.4%和61.4%,也具有显著性差异(P<0.05),但在130例男性人群,其占比分别为29.2%、34.6%和36.2%,无显著性统计学差异(P>0.05)。结论 NAFLD患者存在一些并发T2DM的危险因素,SUA就是一个重要的指标。在早期识别和防止这些危险因素的发生,对降低人群糖尿病的发生率有极大的帮助,应引起临床的高度重视。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 血尿酸, Logistic回归分析, 危险因素

Abstract: Objective The aim of this study was to investigate the changes of serum uric acid (SUA) levels and its clinical implication in patients with nonalcoholic fatty liver disease ((NAFLD)) and type 2 diabetes mellitus (T2DM). Methods The study enrolled 316 patients with NAFLD in our hospital from June 2015 through December 2019, including 218 patients with NAFLD and T2DM, and 98 NAFLD patients without T2DM. The univariate and multivariate Logistic regression analysis was performed in patients with NAFLD to determine the independent risk factors related to T2DM occurrence. Results The proportion of male cases in patients with NAFLD and T2DM was 59.6%, significantly higher than 42.9% (P<0.05) in those without T2DM, the body mass index (BMI) was (27.2±2.9) kg/m², significantly higher than , blood HbA1c was (9.2±2.1)%, significantly higher than , blood high density lipoprotein (HDL) level was (0.9 ±0.2) mmol/l, significantly lower than , blood triglyceride (TG) level was (1.9±0.5) mmol/l, significantly higher than , the SUA was (335.8±72.6) mol/L, significantly higher than , the estimated glomerular filtration rate (eGFR) was (158.4±40.6) ml/min/1.73 m², significantly higher than , the fasting insulin (FINS) level was (5.1±2.6) MIU/L, significantly higher than , and the insulin resistance index (HOMA-IR) was (1.9±1.1), significantly higher than in NAFLD patients without T2DM; we taken gender, BMI, HbA1c, HDL, TG, SUA, eGFR, FINS and HOMA-IR as independent variables, and the multivariate Logistic regression analysis showed that the gender, HbA1c, SUA, FINS and HOMA-IR were (P<0.05)the independent risk factors, while the BMI, HDL, TG and eGFR were not (P>0.05)the independent risk factors for T2DM occurrence in patients with NAFLD; we divided SUA into three groups based on its levels from low to high as SUA-1, SUA-2 and SUA-3, and in 218 NAFLD patients with T2DM, the percentages of T2DM were 21.5%, 32.1% and 46.3%, with significant differences among them(P<0.05), and in 88 female NAFLD patients with T2DM, those were 10.2%, 28.4% and 61.4%, also significant different (P<0.05), while in 130 male patients ,those were 29.2%, 34.6% and 36.2%, not significant different (P>0.05).Conclusion Gender and SUA are independent predictors of T2DM occurrence in patients with NAFLD. The risk factors for T2DM should be found out and some measure should be taken to prevent the progress of NAFLD to severe consequences in clinical practice.

Key words: Nonalcoholic fatty liver disease, Type 2 diabetes mellitus, Serum uric acid, Logistic regression analysis, Risk factors

赵晓春, 钟庆, 刘书宏, 梁尘格, 郭熙清, 温林. 非酒精性脂肪性肝病并发2型糖尿病患者血尿酸水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 55-58.

Zhao Xiaochun,Zhong Qing,Liu Shuhong,et al. Changes and clinical implication of serum uric acid levels in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2021, 24(1): 55-58.

参考文献

[1] Zhang Z, Dai W, Weng S, et al.The association of serum total bile acid withnon-alcoholic fatty liver diseasein Chinese adults: a cross sectional study. Lipids Health Dis, 2020, 19(1):18.
[2] Tsai E, Lee TP. Diagnosis and evaluation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography. Clin Liver Dis, 2018, 22(1):73-92.
[3] Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholicfatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc, 2015, 90(9):1233-1246.
[4] Leite NC, Villela-Nogueira CA, Pannain VL, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int, 2011, 31:700–706.
[5] Portillo Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab, 2014, 100(5):258-263.
[6] Mikolasevic I, Milic S, Turk Wensveen T, et al. Nonalcoholic fatty liver disease - a multisystem disease?. World J Gastroenterol, 2016, 22(43):9488-9505.
[7] Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab, 2013, 98:483–495.
[8] Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007, 30:1212–1218.
[9] Choi H, Kim HC, Song BM, et al. Serum uric acid concentration and metabolic syndrome among elderly Koreans: the Korean Urban Rural Elderly (KURE) study. Arch Gerontol Geriatr, 2016, 64:51-58.
[10] Moon SS. Relationship between serum uric acid level and nonalcoholic fatty liver disease in pre- and postmenopausal women.Ann Nutr Metab, 2013, 62:158-163.
[11] Sirota JC, McFann K, Targher G, et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the national health and nutrition examination survey. Metabolism, 2013, 62:392-399.
[12] Singh K, Kumar P, Joshi A, et al. Study of association of serum uric acid with albuminuria and carotid atherosclerosis in type 2 diabetes mellitus patients. J Family Med Prim Care, 2019, 8(12):4027-4031.
[13] Zhao CC, Wang AP, LiLX, et al. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabet Complication, 2016, 30:1074-1080.
[14] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版). 中华糖尿病杂志, 2018, 10(1):4-67.
[15] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志,2010, 19(6):483-487.
[16] Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009, 150:604-612.
[17] Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) , 2017, 96:e8179.
[18] Xu L, Li T, Yin J, et al. Association between serum uric acid and nonalcoholic fatty liver disease in community patients with type 2 diabetes mellitus. Peer J, 2019, 7:e7563.
[19] Xin Y, Guo Y, Li Y, et al.Effects of sodium glucose cotransporter-2 inhibitors onserumuric acidintype 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi J Biol Sci, 2019, 26(2):421-426.